RESUMEN
AIMS AND METHODS: Oxidant stress is proposed to be an important pathogenic factor in liver damage related to alcohol. The glutathione S-transferases (GSTs) are a group of polymorphic enzymes that are important in protection against oxidant stress. As there is evidence for genetic susceptibility to alcohol-related liver disease we have compared the frequency of polymorphisms of GSTM1, M3, P1, T1 and A1 by polymerase chain reaction (PCR) on leucocyte DNA in patients from North Staffordshire, Birmingham and Liverpool with alcohol-related chronic liver disease heavy drinking and normal local controls. RESULTS: There were no significant differences in GSTM1, GSTM3 or GSTP1 genotype frequencies among patients, drinking and non-drinking controls from the three centres. There was a significant increase in the GSTT1 null Liverpool alcoholic liver disease (ALD) patients compared with corresponding non-drinking controls (26.3 and 14.6%, respectively; P = 0.044, odds ratio (OR) = 2.1, 95% CI = 1.1-4.7) though this was not repeated in the Birmingham and North Staffordshire cohorts. For GSTA1, the -69 CC genotype was associated with increased risk of ALD in the Liverpool group, but a reduced risk in the North Staffordshire group. CONCLUSIONS: We have failed to demonstrate within the limitation of a case-control study a reproducible significant association of GST polymorphisms with susceptibility to ALD but there are suggestions that GSTA1 and GSTT1 warrant further study.
Asunto(s)
Predisposición Genética a la Enfermedad , Glutatión Transferasa/genética , Hepatopatías Alcohólicas/genética , Polimorfismo Genético , Distribución de Chi-Cuadrado , Genotipo , Gutatión-S-Transferasa pi , Humanos , Isoenzimas/genética , Hepatopatías Alcohólicas/enzimología , Estrés Oxidativo , Reacción en Cadena de la PolimerasaRESUMEN
The gene ST7 has been proposed as the multi-tissue tumor-suppressor gene (TSG) at chromosome 7q31.1. However, we have sought and failed to detect the truncating mutations reported to exist in this gene.
Asunto(s)
Genes Supresores de Tumor , Proteínas de la Membrana/genética , Mutación , Cromosomas Humanos Par 7 , Humanos , Pérdida de Heterocigocidad , Polimorfismo Conformacional Retorcido-Simple , Células Tumorales CultivadasRESUMEN
Wnt-induced formation of nuclear Tcf-beta-catenin complexes promotes transcriptional activation of target genes involved in cell fate decisions. Inappropriate expression of Tcf target genes resulting from mutational activation of this pathway is also implicated in tumorigenesis. The C-terminus of beta-catenin is indispensable for the transactivation function, which probably reflects the presence of binding sites for essential transcriptional coactivators such as p300/CBP. However, the precise mechanism of transactivation remains unclear. Here we demonstrate an interaction between beta-catenin and Brg-1, a component of mammalian SWI/SNF and Rsc chromatin-remodelling complexes. A functional consequence of reintroduction of Brg-1 into Brg-1-deficient cells is enhanced activity of a Tcf-responsive reporter gene. Consistent with this, stable expression of inactive forms of Brg-1 in colon carcinoma cell lines specifically inhibits expression of endogenous Tcf target genes. In addition, we observe genetic interactions between the Brg-1 and beta-catenin homologues in flies. We conclude that beta-catenin recruits Brg-1 to Tcf target gene promoters, facilitating chromatin remodelling as a prerequisite for transcriptional activation.
Asunto(s)
Cromatina/fisiología , Proteínas del Citoesqueleto/metabolismo , Regulación de la Expresión Génica , Proteínas Nucleares/metabolismo , Transactivadores , Factores de Transcripción/metabolismo , Sustitución de Aminoácidos , Animales , Línea Celular , Neoplasias del Colon , ADN Helicasas , Drosophila/anatomía & histología , Drosophila/genética , Drosophila/fisiología , Genes Reporteros , Humanos , Luciferasas/análisis , Luciferasas/genética , Mamíferos , Mutagénesis Sitio-Dirigida , Proteínas Nucleares/química , Proteínas Nucleares/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Saccharomyces cerevisiae/genética , Factores de Transcripción/química , Factores de Transcripción/genética , Activación Transcripcional , Transfección , Células Tumorales Cultivadas , beta Catenina , beta-Galactosidasa/análisis , beta-Galactosidasa/genéticaRESUMEN
Many studies suggest that a multi-tissue tumour suppressor gene is located at human chromosome 7q31.1. We have cloned and characterized a novel gene at this locus. The TES gene lies within the minimal region of overlap of several LOH studies and appears to possess the properties of a tumour suppressor. TES is widely expressed and is predicted to encode a protein of 421 amino acids, with three C-terminal LIM domains. Mutation analysis of the coding TES exons in 21 human tumour-derived cell lines revealed the presence of a frameshift mutation in one allele in the breast cancer cell line ZR-75. Methylation of the CpG island at the 5' end of TES appears to be a remarkably frequent finding, occurring in seven out of 10 ovarian carcinomas and in each of the 30 tumour-derived cell lines tested. Moreover, forced expression of TES in HeLa or OVCAR5 cells, resulted in a profound reduction in growth potential, as determined by the colony formation assay. We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation.
Asunto(s)
Cromosomas Humanos Par 7/genética , Genes Supresores de Tumor/genética , Proteínas de Homeodominio/genética , Neoplasias/genética , Proteínas Supresoras de Tumor , Secuencia de Bases , Neoplasias de la Mama/genética , Mapeo Cromosómico , Islas de CpG , Proteínas del Citoesqueleto , Metilación de ADN , Femenino , Mutación del Sistema de Lectura , Células HeLa , Humanos , Proteínas con Dominio LIM , Pérdida de Heterocigocidad , Masculino , Datos de Secuencia Molecular , Neoplasias Ováricas/genética , Neoplasias Pancreáticas/genética , Neoplasias de la Próstata/genética , Proteínas de Unión al ARN , Análisis de Secuencia de ADN , Células Tumorales Cultivadas , Ensayo de Tumor de Célula Madre , Neoplasias de la Vejiga Urinaria/genéticaRESUMEN
We identified CAVEOLIN-1 as a candidate for a tumour suppressor gene mapping to human chromosome 7q31.1. A number of studies suggest that caveolin could function as a tumour suppressor. Expression of caveolin, and in turn the number of caveolae within a cell, are inversely correlated with the transforming ability of numerous oncoproteins, including H-ras, v-abl, and bcr-abl, and caveolin is a major transformation-dependent substrate of v-src. Heterologous expression of caveolin has been shown to abrogate anchorage-independent growth and induce apoptosis in transformed fibroblasts and also to suppress anchorage-independent growth in human mammary carcinoma cells. We have analysed the status and expression of the human CAVEOLIN-1 gene in primary tumours and tumour-derived cell lines. We found no evidence for mutation of CAVEOLIN-1 in human cancers. Additionally, we found that while the first two exons of CAVEOLIN-1 are associated with a CpG island, this is not methylated in either primary tumours or in tumour-derived cell lines in which Caveolin-1 expression is low or undetectable. The level of expression of Caveolin-1 does not correlate with loss of heterozygosity at the CAVEOLIN-1 locus in these same cell lines. Contrary to other published studies, we have shown that CAVEOLIN-1 is not expressed in normal breast ductal epithelial cells in vivo. CAVEOLIN-1 is however highly expressed in breast myoepithelial cells and its expression is retained in tumours derived from breast myoepithelium. Together our data refute a role for CAVEOLIN-1 as a breast tumour suppressor gene in vivo.
Asunto(s)
Caveolinas , Cromosomas Humanos Par 7 , Genes Supresores de Tumor , Proteínas de la Membrana/genética , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Caveolina 1 , Mapeo Cromosómico , Islas de CpG , Metilación de ADN , Exones , Femenino , Expresión Génica , Marcadores Genéticos , Humanos , Mutagénesis , Mioepitelioma/metabolismo , Mioepitelioma/patología , Células Tumorales CultivadasRESUMEN
Human squamous cell carcinomas (SCC) frequently express elevated levels of epidermal growth factor receptor (EGFR). EGFR overexpression in SCC-derived cell lines correlates with their ability to invade in an in vitro invasion assay in response to EGF, whereas benign epidermal cells, which express low levels of EGFR, do not invade. EGF-induced invasion of SCC-derived A431 cells is inhibited by sustained expression of the dominant negative mutant of c-Jun, TAM67, suggesting a role for the transcription factor AP-1 (activator protein-1) in regulating invasion. Significantly, we establish that sustained TAM67 expression inhibits growth factor-induced cell motility and the reorganization of the cytoskeleton and cell-shape changes essential for this process: TAM67 expression inhibits EGF-induced membrane ruffling, lamellipodia formation, cortical actin polymerization and cell rounding. Introduction of a dominant negative mutant of Rac and of the Rho inhibitor C3 transferase into A431 cells indicates that EGF-induced membrane ruffling and lamellipodia formation are regulated by Rac, whereas EGF-induced cortical actin polymerization and cell rounding are controlled by Rho. Constitutively activated mutants of Rac or Rho introduced into A431 or A431 cells expressing TAM67 (TA cells) induce equivalent actin cytoskeletal rearrangements, suggesting that the effector pathways downstream of Rac and Rho required for these responses are unimpaired by sustained TAM67 expression. However, EGF-induced translocation of Rac to the cell membrane, which is associated with its activation, is defective in TA cells. Our data establish a novel link between AP-1 activity and EGFR activation of Rac and Rho, which in turn mediate the actin cytoskeletal rearrangements required for cell motility and invasion.
Asunto(s)
Factor de Crecimiento Epidérmico/metabolismo , GTP Fosfohidrolasas/metabolismo , Proteínas/metabolismo , Factor de Transcripción AP-1/metabolismo , Actinas/metabolismo , Línea Celular Transformada , Tamaño de la Célula/fisiología , Citoesqueleto/química , Citoesqueleto/metabolismo , Proteínas Activadoras de GTPasa , Expresión Génica/fisiología , Queratinocitos/química , Queratinocitos/citología , Queratinocitos/enzimología , Riñón/citología , Mutagénesis/fisiología , Proteínas Proto-Oncogénicas c-jun/genética , Proteínas Proto-Oncogénicas c-jun/metabolismo , Transducción de Señal/fisiología , TransfecciónRESUMEN
Cancer of the prostate gland is the highest unavoidable cause of cancer mortality in men. The recent identification and characterisation of genes specifically expressed in prostate cancer helps us to understand its molecular basis and should offer new therapeutic avenues to combat this disease.